The global antibiotic pipeline has shrunk by 35% between 2021 and 2026 according to the AMR Benchmark report from the Access to Medicine Foundation. Yet seven molecules in late-stage development could revolutionize the treatment of the most resistant infections. This contradiction reveals a sector in full transformation where innovation attempts to survive the failing economics of antimicrobials.

Major Firms Back Out, Biotech Holds On

The hemorrhage is massive in the laboratories of pharmaceutical giants. Pfizer, GSK and Novartis have drastically reduced their antimicrobial investments since 2021, concentrating their R&D budgets on oncology and rare diseases where financial returns are significantly higher. The profitability of antibiotics is particularly low compared to other medications, no longer weighing against therapies costing $200,000 per patient.

This abandonment by the major players leaves the field to specialized biotech companies. The seven most promising molecules are being developed by GSK, Otsuka, Shionogi, BioVersys, F2G, Innoviva and Venatorx. These companies compensate for their smaller size with pointed expertise: they directly target the resistance mechanisms that beta-lactamases develop against conventional antibiotics.

The molecules in late-stage development show promising results in clinical trials against resistant infections. The improvement in therapeutic performance is attracting investors to this evolving sector.

Tebipenem Pivoxil and Plazomicin: Weapons Against Superbacteria

The most advanced molecules target the deadliest hospital infections. These new antibiotics treat complicated urinary tract infections caused by carbapenemase-producing Enterobacteriaceae. These bacteria represent a major threat with a high mortality rate due to lack of effective treatment.

Clinical trials conducted in several countries demonstrate the efficacy of these new molecules with results superior to reference treatments. More crucially, some can be administered orally, allowing outpatient treatment where carbapenems require hospitalization averaging 12 days.

New approaches target pulmonary infections from multidrug-resistant Pseudomonas aeruginosa. This bacterium, responsible for 51,000 hospital infections annually in the United States, develops cross-resistance against five families of antibiotics simultaneously. The new molecules bypass this resistance by targeting ribosomal proteins previously spared by bacterial defense mechanisms.

Innovation Facing the Broken Economics of Antibiotics

Innovation alone is insufficient to resolve the crisis. The economic model for antibiotics remains fundamentally broken: the more effective a medication is, the less it is used to preserve its activity. This conservation logic limits sales to approximately $46 million on average for an antibiotic, compared to approximately $600 million for an oral anticoagulant and $1,500 million for an oral antidiabetic.

The PASTEUR Act has been reintroduced several times in Congress since 2020 but has never been adopted. This “subscription model” mechanism proposed would guarantee the PASTEUR Act provides up to $6 billion total, with individual contracts ranging from $750 million to $3 billion for companies developing critical antibiotics, regardless of volumes sold.

Europe is developing its own financing mechanisms. HERA has a total budget of approximately 6 billion euros (2022-2027) for various public health initiatives. France directly finances three national biotech companies through the health innovation fund, while Germany is betting on public-private partnerships with Bayer and Boehringer Ingelheim. This race to develop incentive mechanisms reveals a belated but massive awareness: without public intervention, the global antimicrobial arsenal will be depleted in less than ten years.

Asia Becomes the Laboratory of Future Antibiotics

The geography of antimicrobial innovation is shifting toward Asia. China now has 23 specialized biotech companies compared to 8 in 2020, supported by $950 million in public investments. BGI Genomics is developing an unprecedented approach: real-time identification of resistance genes through next-generation sequencing, enabling personalized treatment in 4 hours versus 48 hours currently.

India is betting on mass production of generic antibiotics combined with new resistance inhibitors. Aurobindo Pharma is testing a ceftazidime-avibactam-relebactam combination that shows promising activity against resistant Enterobacter cloacae strains, although definitive results still require further study. This multi-combination strategy could transform old molecules into effective weapons against emerging resistance.

Bacterial Resistance: When Microbes Evolve Faster Than Laboratories

The race between innovation and resistance is accelerating dangerously. Bacteria develop defense mechanisms against new molecules in 18 months according to laboratory observations, compared to 3 years for previous aminoglycosides. This rapid adaptation forces companies to simultaneously develop multiple generations of antibiotics, already testing potential successors before even regulatory approval of the first molecules.

Global surveillance data reveal emerging cross-resistance that concerns researchers. Some strains of Acinetobacter baumannii show signs of reduced susceptibility to new molecules after limited clinical exposure. This speed of bacterial adaptation calls into question the useful lifespan of new antibiotics, now estimated at 5-8 years compared to 15 years in the 1990s.

The response involves unprecedented preservation strategies. Dutch hospitals are testing cyclic use of antibiotics: quarterly rotation between new molecules and conventional antibiotics to maintain selective pressure at a supportable level. This approach reduces emergence of resistance by 35% but requires international coordination that health systems still struggle to implement.

The battle against antimicrobial resistance is being fought on multiple fronts simultaneously: molecular innovation, economic reform and international cooperation. The seven promising molecules in the 2026 pipeline offer temporary respite, but their success will depend as much on financing mechanisms as on their intrinsic efficacy. The stakes go beyond pharmacology: it is a matter of rebuilding an innovation ecosystem capable of sustainably outpacing bacterial evolution.

Sources: